Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with severe skin disorders and other related conditions. The company operates primarily in the healthcare sector, with a strong emphasis on photoprotection and skin repair. Its flagship product, SCENESSE (afamelanotide), is designed to provide protection against the harmful effects of ultraviolet (UV) light and is particularly beneficial for individuals with erythropoietic protoporphyria (EPP), a rare genetic disease that causes extreme sensitivity to sunlight.